Novo Nordisk’s trial of semaglutide for obesity meets primary endpoint
Novo Nordisk has reported that its Phase IIIb STEP UP trial, aimed to assess the safety and efficacy of subcutaneous ...
clinicaltrialsarena4m
Novo Nordisk’s high-dose Wegovy increases weight loss and remains safe
Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.
The Financial Express34m
Tirzepatide for weight loss: All you need to know
This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...